<DOC>
	<DOCNO>NCT02564952</DOCNO>
	<brief_summary>This trial consist 2 part : double-blinded phase open-label extension phase . The open-label extension phase describe record . All participant receive dose GWP42003-P . However , investigator may subsequently decrease increase participant 's dose optimal dose find .</brief_summary>
	<brief_title>An Open-label Extension Trial Investigate Possible Drug-drug Interactions Between Clobazam Cannabidiol</brief_title>
	<detailed_description />
	<mesh_term>Clobazam</mesh_term>
	<criteria>Key Participant must epilepsy , determine investigator , take clobazam ( CLB ) . Participant must document magnetic resonance imaging/computerized tomography brain ruling progressive neurologic condition . Participant must take CLB 2 antiepileptic drug ( AEDs ) course trial . Key Patient clinically significant unstable medical condition epilepsy . Participants CLB dose 20 mg per day . Participants take CLB intermittently rescue medication . Participant history symptom relate drop blood pressure due postural change ( e.g. , dizziness , lightheadedness , blur vision , palpitation , weakness , syncope ) . Participant history suicidal behavior suicidal ideation type 4 5 CSSRS last month screen visit blind phase trial . Participant clinically relevant symptom clinically significant illness 4 week prior screen enrollment blind phase trial , epilepsy . Participant currently use past use recreational medicinal cannabis , synthetic cannabinoidbased medication ( include SativexÂ® ) within 3 month prior trial entry . Participant know suspected history drug abuse addiction . Participant unwilling abstain recreational medicinal cannabis , synthetic cannabinoid base medication ( include Sativex ) duration trial . Participant know suspected hypersensitivity cannabinoids excipients Investigational Medicinal Product ( IMP ) , e.g. , sesame oil .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cannabidiol</keyword>
	<keyword>GWP42003-P</keyword>
	<keyword>Clobazam</keyword>
	<keyword>Epidiolex</keyword>
</DOC>